Abstract 1747P
Background
Cervical cancer patients' age is relatively young (considering only 35-39 and not 60-64). At this young age, patients might consider birth planning and other sexual health considerations such as vaginal rehabilitation.
Methods
A call for answers to a survey was published and patients and verified survivors were invited to respond voluntarily and anonymously through a coded and encrypted web form.
Results
116 women responded to the survey (age 21-72, median=42, age range at diagnosis 18-65). 8% were diagnosed with CIN1-2, 43% with CIN3, 20% with stage 1, 7% with stage 2, 10% with stages 3-4, 12% did not know how to answer. Past treatments were recorded. 84% of those required to use a vaginal dilator did not do so (results were modified in accordance to guidelines). At childbearing age [67 women, ages 21-45, median=37; 55.22% CIN3, 19.4% stage 1, 5.97% stage 2, 5.97% stages 3-4, 13.43% did not know how to answer; 77.61% were sexually active with a single known partner], only 58.2% recall having a discussion with their physician regarding fertility preservation, before beginning treatments. 32.83% recall such a discussion afterwards. 11.94% give birth after illness or had a child thanks to a surrogate mother.
Conclusions
This study underscores the need for greater attention to patients’ sexual health and fertility aspects before and after completion of treatments. There is a need in coordinate patients' expectations regarding birth planning and in making the information regarding vaginal dilator accessible. Research involving a larger sample size may help to better support the information needs of survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
HaBait Shel Bar – Israel’s Women’s Cancer Association (RA).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1746P - Unintended consequences: Working time directives and oncology staff implications
Presenter: Simon Barry
Session: Poster session 23
1748P - Tackling childhood obesity epidemic on southern Europe through soft drink advertisement policies: Should oncology societies have a say?
Presenter: Konstantinos Kamposioras
Session: Poster session 23
1749P - Prevention of modifiable cancer risks in informal family caregivers of cancer patients: Implementation and evaluation of a personalised primary prevention intervention (PREV-AIDANT)
Presenter: Beatrice Fervers
Session: Poster session 23
1751P - Re-ranking cancer mortality using years of life lost
Presenter: Cecilia Radkiewicz
Session: Poster session 23
1752P - Clinical benefit of immunotherapies in advanced cancer in France: A population-based estimate from 2014 to 2021
Presenter: Isabelle Borget
Session: Poster session 23
1753P - Universal DPYD genotyping in patients with gastrointestinal malignancies: Real-world data from a single institution in Italy
Presenter: Claudia Cardone
Session: Poster session 23
1754P - Towards a next-generation sequencing/comprehensive genomic profiling value framework: Systematic review for identifying new domains and adapting a diagnostic test value framework in Europe
Presenter: Federico Augustovski
Session: Poster session 23
1755P - Carbohydrate quality index and incidence of obesity-related cancers: The Seguimiento Universidad de Navarra (SUN) project
Presenter: Maria Olmedo López-frías
Session: Poster session 23
1756P - Vizcan: A Swedish population-based study to address cancer outcomes using an interactive platform
Presenter: Anders Berglund
Session: Poster session 23